BridgeBio Pharma, Inc. (BBIO) — Institutional Holders, Q2 2026 (page 6)
508 institutional investment managers reported a BBIO position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $16.1B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 501 to 508. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
BBIO 13F holders ranked 501–508 of 508
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 501 | Quaker Wealth Management#501 · 1 sh | 1 | $75.00 | — | -50.0% |
| 502 | MARYLAND CAPITAL ADVISORS#502 · 1 sh | 1 | $75.00 | — | — |
| 503 | 3 FACTOR INDEXING#503 · 1 sh | 1 | $75.00 | — | 0.0% |
| 504 | Plante Moran Financial Advisors#504 · 1 sh | 1 | $74.00 | 0.00% | New |
| 505 | NOMURA ASSET MANAGEMENT LTD#505 · 0 sh | 0 | $0.00 | 0.00% | New |
| 506 | Navigoe#506 · 2 sh | 2 | $0.00 | 0.00% | New |
| 507 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#507 · 168,265 sh | 168,265 | — | — | +1.5% |
| 508 | Context Capital Management#508 · 56,666,000 sh | 56,666,000 | — | — | -20.5% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.